SVB Securities analyst Research Report) on August 7. The company’s shares closed yesterday at $170.67.
According to TipRanks, Risinger is a 3-star analyst with an average return of 3.2% and a 47.62% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Sanofi, and Eli Lilly & Co.
Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $189.17.
JNJ market cap is currently $447.4B and has a P/E ratio of 24.74.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year. Most recently, in June 2022, Wengel Kathryn E, the EVP, Chief GSC Officer of JNJ sold 40,000.00 shares for a total of $6,920,000.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Read More on JNJ:
- SVB Securities Keeps Their Buy Rating on 908 Devices (MASS)
- SVB Securities Keeps Their Buy Rating on Gossamer Bio (GOSS)
- SVB Securities Keeps Their Buy Rating on Immatics (IMTX)
- Intra-Cellular Therapies (ITCI) Receives a Buy from SVB Securities
- SVB Securities Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)